LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Clinical trial NCT01125566 · COMPLETED

Trial details

NCT number: NCT01125566
Sponsor: Boehringer Ingelheim
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2010-06-22
Primary completion: 2013-06-08
Enrollment: 508

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.